Virtual Library

Start Your Search

Feliciano Barr



Author of

  • +

    IASLC Pre-Conference School of Nursing (ID 3)

    • Event: LALCA 2019
    • Type: Invited Speaker Session
    • Track:
    • Presentations: 2
    • +

      PC3.08 - Chemotherapy, There is Still a Role (ID 33)

      09:00 - 15:30  |  Author(s): Feliciano Barr

      • Abstract
      • Slides

      Abstract not provided

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      PC3.10 - Targeted Therapy and Side Effect Management: Case Studies (ID 35)

      09:00 - 15:30  |  Author(s): Feliciano Barr

      • Abstract
      • Slides

      Abstract not provided

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    IASLC Pre-Conference School of Thoracic Oncology (ID 1)

    • Event: LALCA 2019
    • Type: Invited Speaker Session
    • Track:
    • Presentations: 1
    • +

      PC1.15 - Building Your Multidisciplinary Team (ID 15)

      09:00 - 15:30  |  Author(s): Feliciano Barr

      • Abstract
      • Slides

      Abstract not provided

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    Session 9: Poster Discussion # 1: Diagnosis, Early Stage and Locally Advanced (ID 23)

    • Event: LALCA 2019
    • Type: Poster Discussion Session
    • Track:
    • Presentations: 1
    • +

      F9.05 - Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced Non-small-cell Lung Cancer (CLICAP-ABs) (ID 94)

      16:15 - 17:15  |  Author(s): Feliciano Barr

      • Abstract
      • Slides

      Background:
      The composition of gut microbiota affects antitumor immune responses, as well as preclinical and clinical outcomes following immune checkpoint inhibitors (ICI) in cancer. Antibiotics (ATB) alter gut microbiota diversity and composition leading to dysbiosis, which may influence the effectiveness of ICI.

      Method:
      We examined patients with advanced non-small-cell lung cancer (NSCLC) treated with anti-programmed cell death ligand-1 mAb monotherapy alone or in combination in three different countries of Latin America. Those receiving ATB within 30 days of beginning ICI were compared with those who did not. Objective response, progression free survival (PFS) and overall survival (OS) were assessed.

      Results:
      18 of 140 (13%) NSCLC patients received ATB. The most commonly used ATB were b-lactam or quinolones for pneumonia or urinary tract infections. In NSCLC patients, ATB was associated with 4 cases of primary PD (28.6% versus 31.5%, P=0.818), non-significant decreased PFS (median 2.66 versus 1.94 months, HR 1.63, [95% CI 0.71-3.72], P=0.247) and significantly deleterious OS (median 12.42 versus 2.04 months, HR 2.3, [95% CI 1.08-4.95], P=0.03). In multivariate analyses, the impact of ATB remained significant for OS.

      Conclusion:
      ATB were associated with reduced clinical benefit from ICI in Hispanic patients with NSCLC. Modulation of ATB-related dysbiosis and gut microbiota composition may be a strategy to improve clinical outcomes with ICI.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.